Pfizer's Vyndamax (tafamidis)
Pricing, marketing, PBM rebates and patent settlements for a rare heart disease drug
Vyndamax and its sister product Vyndaqel are Pfizer's treatments for transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive and often fatal heart disease that mainly affects older adults. Since approval in 2019 the drug has been criticised as one of the most overpriced medicines in cardiology. This article sets out each strand of the controversy: price, value, patient costs, rebates, marketing and generic delay.
Questions
What are Vyndamax and Vyndaqel, and what do they treat?
Both contain tafamidis, a drug that stabilises the TTR protein to prevent amyloid deposits — approved in 2019 with orphan drug designation for a disease that kills within about 2.5 years if untreated.
Both contain tafamidis, a drug that stabilises the transthyretin (TTR) protein so it is less likely to misfold into amyloid deposits that stiffen the heart. Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) were approved by the FDA in 2019 with orphan drug designation. ATTR-CM leads to heart failure and death, typically within about 2.5 years if untreated, and BridgeBio estimates there are around 240,000 US patients, many undiagnosed. Pfizer had this market entirely to itself for five years, which is central to many of the criticisms that followed.
Q2How much does Vyndamax cost, and how has the price changed?
Launched at $225,000 — the most expensive cardiovascular drug on the market — the list price reached nearly $268,000 by 2024, while the net price of ~$194,000 still far exceeds what ICER considers cost-effective.
At launch in 2019 the list price was $225,000 a year, making tafamidis the most expensive cardiovascular drug on the market. The pivotal trial's own principal investigator, Dr Mathew Maurer, called the price unjustified and "a particularly egregious example of price gouging." According to a public comment filed with the FDA, the list price rose to $234,900 by 2022. By 2024, ICER reported a wholesale acquisition cost of nearly $268,000, or about $194,000 after discounts. That gap of roughly $74,000 between list and net price represents rebates and discounts paid to intermediaries and payers, which matters because many patients' cost-sharing is calculated on the list price rather than the net price.
Q3What did ICER conclude about Vyndamax's value?
A draft report suggested $5,200–$10,400 per year; the final October 2024 report settled on an 85–95% required discount — meaning a fair price of $13,600–$39,000 against a list price approaching $268,000.
The Institute for Clinical and Economic Review, an independent non-profit that assesses drug prices, published a draft report in July 2024 suggesting tafamidis should cost only $5,200 to $10,400 a year, implying a discount of at least 96%. After modelling changes, including how mortality was estimated, the final October 2024 report concluded tafamidis needed a discount of 85% to 95%, equating to $13,600 to $39,000 a year. ICER's findings are not binding, but payers use them in coverage negotiations.
Q4How does the US price compare with other countries?
A public comment to the FDA showed the US list price of $234,900 far exceeded Japan's $93,600 and UK prices — and Medicare cannot negotiate tafamidis because researchers classify it as a "sole orphan" drug exempt under the IRA.
A public comment submitted to the FDA in a patent term restoration proceeding for Vyndamax argued that the US list price of $234,900 was markedly higher than in Japan, at $93,600, and in the United Kingdom. The same comment noted Pfizer's 2023 annual report disclosed $3.3 billion from the tafamidis family and urged the FDA to deny a patent term extension so generic competition could arrive sooner. Such price gaps are frequently cited in arguments that US patients and taxpayers subsidise lower prices abroad. Medicare cannot currently negotiate tafamidis's price either: it is not on the 2028 selected-drug list, and researchers have identified it as a "sole orphan" drug exempt from negotiation under the Inflation Reduction Act.
Q5What do patients actually pay out of pocket?
A 2020 JAMA Cardiology study found the median 30-day cost before assistance was $1,909 — seven patients never received the drug at all, and 28 of those who did relied on copay assistance to get it at no cost.
Because tafamidis is a pharmacy drug, patients on Medicare Part D or commercial plans often face coinsurance calculated on its high list price. A 2020 JAMA Cardiology study of 50 patients at Oregon Health & Science University found the median 30-day out-of-pocket cost before assistance was $1,909. Seven patients never received the drug: three could not afford it, two declined assistance and one died before getting it. Of the 43 who did, 28 relied on copay assistance from a foundation or from Pfizer to get it at no cost. Maurer reported that his patients paid roughly $1,000 to $2,000 each month. Critics argue this dependence on assistance programmes masks the true cost and still leaves gaps.
Q6How do PBM rebates help Pfizer's Vyndamax?
A ~$74,000 gap between Vyndamax's list and net price flows through the supply chain as rebates — calculated on list price, meaning patients' coinsurance is higher, a dynamic the FTC has alleged in the insulin market favours high-list-price incumbents.
Pfizer does not disclose its tafamidis rebate contracts, but the way Medicare Part D rebates work explains why critics believe they favour the incumbent. Manufacturers pay rebates to PBMs, which share them with plans, to win formulary placement, with the aim of including their product while excluding competitors or securing preferred status. A drug with around 75% of prescriptions can offer rebates across a far larger patient base than a newcomer. Rebates are typically calculated from list price, and patients' coinsurance is usually applied to the price before the rebate is subtracted, so a high list price can suit both manufacturer and PBM while patients pay more. ICER put tafamidis at nearly $268,000 list against about $194,000 net, a gap of about $74,000 per patient-year flowing through the supply chain. From 2025, plans bear 60% of catastrophic-phase costs, and Milliman says plans may demand much higher rebates on high-cost drugs as a result. The FTC has alleged, in the insulin market, that PBMs favoured high-list-price, high-rebate products.
Q7What are the marketing concerns about Vyndamax?
In September 2025 Pfizer was accused of showing a video at a medical meeting describing Vyndamax as the first and only approved treatment — omitting two approved rivals — and a German court ordered it to stop claiming "near-complete stabilisation".
Critics raise concerns about how Vyndamax is described to patients and doctors now that alternatives exist. Patient advocates have objected to language presenting Vyndamax as the "only" once-daily capsule for ATTR-CM, arguing it may lead patients to believe they have fewer options than they do. The same report notes that Pfizer's materials direct patients to Amyloidosis Support Groups, to which Pfizer's historic disclosures show a $50,000 contribution, raising questions about industry funding of advocacy groups. In September 2025 Pfizer was accused of showing a video at a medical meeting describing Vyndamax as the first and only approved treatment, omitting two approved rivals, and that another Pfizer comparison was not based on fair and comparable standards.
Q8What is the controversy over Vyndamax's patents and generic entry?
Settlements with three generic makers extend US entry to June 2031 — from an expected 2028 — on undisclosed terms, drawing scrutiny as potential "pay for delay" arrangements that BioPharma Dive notes have long attracted federal antitrust concern.
Tafamidis was expected to lose exclusivity around 2028. From 2023, generic makers challenged its patents; Pfizer sued Dexcel, Hikma and Cipla and settled with all three in April 2026. The settlements extend the US generic entry date to June 1, 2031, pending other litigation, and BridgeBio's CEO has said Pfizer's broader patent estate, including crystalline form patents, extends to 2035. BioPharma Dive noted that "pay for delay" agreements have long drawn scrutiny from federal regulators as tools to impede price competition. The terms have not been disclosed, so whether Pfizer transferred value to the generic companies, the key test under antitrust law, is unknown.
Q9Why did Pfizer discontinue Vyndaqel, and why has the move raised questions?
Vyndaqel was due to lose patent protection in 2028; Vyndamax is protected to 2035. Moving patients to the better-protected formulation before generics arrive — what critics call "product hopping" — means Vyndaqel use may be minimal by the time its generics arrive.
In August 2025 Pfizer said it would discontinue Vyndaqel in the US at the end of 2025 and move patients to Vyndamax. The two contain the same active ingredient: Vyndaqel is four daily capsules of tafamidis meglumine, Vyndamax a single daily capsule. Pfizer said the change improves convenience and was made in consultation with experts and patient advocates, and insurers such as UnitedHealthcare told Medicare members they needed new prescriptions for Vyndamax. The timing drew attention because the two formulations have different patent protection. Vyndaqel was due to lose protection in 2028, while Vyndamax is covered by a patent on a specific crystalline form that runs to 2035. A patent analysis noted that this crystalline-form patent is not listed for Vyndaqel, so generic Vyndaqel could have arrived earlier and, if doctors treated the two as interchangeable, eroded both. Jefferies analysts observed that by the time Vyndaqel generics enter the market, clinical use of the Vyndaqel formulation may already be minimal. Moving patients to a newer, better-protected version before generics arrive is what critics call "product hopping". No regulator has found Pfizer's decision anticompetitive, and Vyndaqel accounted for fewer than 20% of tafamidis prescriptions when the change was announced.
Q10How does Vyndamax compare with its new competitors?
BridgeBio's Attruby (approved Nov 2024) achieves near-complete stabilisation and showed 34% lower worsening risk vs tafamidis in real-world data; Alnylam's Amvuttra (approved Mar 2025) silences TTR production at $476,000/year. A July 2026 trial failure for a rival silencer reinforced stabilisers as frontline treatment.
Vyndamax now competes with BridgeBio's Attruby (acoramidis), approved on November 22, 2024, and Alnylam's Amvuttra (vutrisiran), approved for ATTR-CM in March 2025. Attruby is also a stabiliser; BridgeBio priced it at about $244,000 a year, below tafamidis. Attruby it is the only drug ATTR-CM drug that achieves "near-complete stabilization". A real-world study of 618 new patients found a 34% lower risk of clinical worsening with acoramidis than tafamidis over about 4.6 months. Amvuttra is a "silencer" that reduces TTR production, priced at about $476,000 a year. A second silencer, AstraZeneca and Ionis's Wainua (eplontersen), failed its ATTR-CM outcomes trial in July 2026. Most participants were already on a stabiliser, and Wainua showed no added benefit on top of stabiliser therapy. Analysts said the result "benefits stabilizers" and reinforces them as frontline treatment.
Q11What is the overall assessment of the Vyndamax controversy?
At $6.38 billion in 2025 revenue, tafamidis is about 10% of Pfizer's total — making every aspect of its franchise, from a list price ICER says needs an 85–95% cut, to patent settlements delaying generics to 2031, a high-stakes test of pharmaceutical accountability.
Vyndamax is financially crucial to Pfizer, earning $6.38 billion in 2025, about 10% of company revenue. The controversy is about everything around the molecule. On price, the trial's own investigator called the launch price gouging, the list price has risen from $225,000 to nearly $268,000, and ICER says it needs an 85% to 95% discount to be cost-effective. On access and public cost, patients have depended on copay assistance, and after the 2024 Medicare Part D changes cut most patients' costs to $0 per claim, Vyndamax claims rose 86%, with taxpayers bearing much of the bill; Medicare cannot negotiate the price because researchers classify tafamidis as a sole orphan drug. On competition, patent settlements delay generics to 2031, the discontinuation of Vyndaqel ahead of a 2028 patent expiry moved patients to a formulation protected to 2035, and rebate structures favour the incumbent. On promotion, Pfizer has been accused of misleading marketing claims, including over a disputed German ruling. Together they show how a company can maximise and prolong returns from a breakthrough drug, and why critics argue the rules should change. The key tests ahead are any antitrust review of the settlements and whether Congress narrows the orphan exemption.